Cellcept Tablets 500Mg (5 Strip = 50 Tablets)

Advanced Protection Against Organ Rejection

CellCept Tablets 500 mg are a prescription immunosuppressant medication used in the prevention of organ rejection in transplant recipients. Containing the active ingredient mycophenolate mofetil, CellCept plays a vital role in managing the immune response following kidney, heart, or liver transplantation. It is commonly prescribed as part of a combination immunosuppressive regimen to support long-term graft acceptance.

How CellCept Works in the Body

Mycophenolate mofetil works by targeting the immune system at a cellular level. It is converted in the body to mycophenolic acid, which inhibits the enzyme inosine monophosphate dehydrogenase. This enzyme is essential for purine synthesis in human lymphocytes. By blocking this pathway, CellCept suppresses the proliferation of both T-lymphocytes and B-lymphocytes, which are responsible for initiating immune-mediated rejection of transplanted organs.

Indicated for Multiple Organ Transplants

CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney, heart, or liver transplants. It is used in adult and pediatric patients aged three months and older, as part of a comprehensive immunosuppressive treatment plan. The medication is administered alongside cyclosporine and corticosteroids to provide balanced and effective immune suppression.

Flexible Dosing Under Medical Supervision

Dosing of CellCept varies depending on the type of transplant and patient profile. For renal transplant patients, a standard adult dose of 1 gram twice daily is recommended. Higher doses are used in cardiac and hepatic transplant patients. Elderly patients generally follow the same dosing guidelines. All dosing should be determined and monitored by a qualified healthcare professional experienced in transplant medicine.

Important Safety and Monitoring Considerations

Because CellCept suppresses the immune system, patients are at an increased risk of infections and certain malignancies, including lymphoma. Regular monitoring is essential, including complete blood counts performed at frequent intervals, especially during the first year of therapy. Patients should also be monitored for signs of infection, organ rejection, and hematological abnormalities.

CellCept is contraindicated in pregnancy and lactation due to the increased risk of pregnancy loss and congenital malformations. Women of childbearing potential must use effective contraception during treatment. The medication should only be administered in specialized healthcare settings equipped for transplant care.

Drug Interactions and Precautions

CellCept may interact with several medications, including antiviral agents, phosphate binders, antibiotics, and other immunosuppressants. It may also reduce the effectiveness of live vaccines. Patients should inform their healthcare provider about all medicines they are taking before starting therapy.

Reliable Immunosuppression for Long-Term Graft Survival

CellCept Tablets 500 mg are a cornerstone of modern transplant immunosuppressive therapy. When used correctly under expert medical supervision, they help protect transplanted organs, reduce rejection risk, and support long-term transplant success.

Call to Action

If you or your patient require proven immunosuppressive protection following organ transplantation, consult a transplant specialist about CellCept Tablets 500 mg. Use this trusted therapy under professional supervision to support graft survival and long-term transplant outcomes.